|FOR IMMEDIATE RELEASE
February 20, 2008
|CONTACT: James F. Jorkasky
NAEVR SUPPORTS MAJOR EVENTS IN MARCH 2008 TO EXPAND GLAUCOMA AWARENESS AND EDUCATE ABOUT
THE IMPACT OF NEI-FUNDED RESEARCH INTO THE DISEASE
(Washington, D.C.) Today, the National Alliance for Eye and Vision Research (NAEVR) announced its support for two major events to be held in March 2008 to expand awareness of the incidence and economic burden of glaucoma, as well as to educate about the impact of research into the disease that is funded by the National Eye Institute (NEI) within the National Institutes of Health (NIH). Glaucoma, the second leading cause of preventable vision loss in the U.S., is a group of diseases that damage the optic nerve and lead to vision loss. Every American over the age of 60 is at risk of developing glaucoma, which disproportionately affects minority populations. African Americans have a three times greater risk of developing this disease than white Americans, and it is the leading cause of irreversible vision loss in both African Americans and Hispanics.
- On March 6, the American Glaucoma Society is presenting a Capitol Hill Briefing and Screening entitled Glaucoma: Awareness and Early Detection Can Prevent Blindness which will feature real-time optic nerve and pressure evaluation of the eye. The event, to be held in Room B-369 of the House Rayburn Office Building from 11:30 am – 1:30 pm, is one of more than 300 events being held globally during the first-ever World Glaucoma Day—March 6. The AGS is also conducting an Advocacy Day, and NAEVR is providing its request for increased Fiscal Year 2009 NIH/NEI funding for use by AGS members in their planned visits in more than 100 Congressional offices.
- On March 13-14, the NEI, in conjunction with the Food and Drug Administration (FDA) and its Center for Drug Evaluation and Research (CDER), is presenting the NEI/FDA CDER Clinical Drug Trial Design and Endpoints Symposium. The meeting, to be held in the Natcher Auditorium on the NIH Campus, will explore how new outcomes measures may facilitate glaucoma therapy clinical trials. The meeting was organized in cooperation with NAEVR and ARVO, which is also managing the meeting, full details of which appear at www.arvo.org/endpoints.
The National Alliance for Eye and Vision Research (NAEVR) is a non-profit advocacy coalition comprised of 55 professional, consumer, and industry organizations involved in eye and vision research. NAEVR’s goal is to achieve the best vision for all Americans through advocacy and public education for eye and vision research sponsored by the National Institutes of Health (NIH), the National Eye Institute (NEI) and other federal research entities. Visit NAEVR’s Web site at www.eyeresearch.org.